Literature DB >> 21638004

Geographic differences in the increasing ESRD rate have disappeared in Japan.

Tamaki Wakamatsu-Yamanaka1, Michio Fukuda2, Ryo Sato1, Takehiro Naito1, Hiroyuki Togawa1, Tatsuya Tomonari1, Yoko Kato1, Toshiyuki Miura1, Masashi Mizuno1, Tadashi Ichikawa1, Sota Miyagi1, Yuichi Shirasawa1, Akinori Ito1, Atsuhiro Yoshida1, Genjiro Kimura1.   

Abstract

BACKGROUND: We previously showed that there are marked geographic differences in the incidence of end-stage renal disease (ESRD) within Japan. In addition, the use of renin-angiotensin system inhibitors was found to be inversely correlated with the increasing ESRD rate. It was recently demonstrated that the incidence of ESRD due to diabetic nephropathy is declining in both Europe and USA. Therefore, we investigated the increasing ESRD rate and its geographic difference in Japan.
METHODS: Each year, the Japanese Society for Dialysis Therapy reports the numbers of patients initiating maintenance dialysis therapy in each prefecture of Japan. We used old (1984-1991) and recent (2001-2008) data to compare the increasing ESRD rate, which was estimated from the slope of the regression line of the annual incidence corrected for population, between the two periods in 11 regions of Japan.
RESULTS: Increasing ESRD rate almost halved, from 11.1 ± 5.6 to 5.4 ± 0.7/million per year from the old to the recent period. Deceleration of the increasing ESRD rate from the old to the recent period was correlated with the incidence in the old period across 11 regions (r = 0.81, p < 0.003); i.e., the deceleration was greater in the regions where ESRD incidence had been higher. Whereas the increasing ESRD rate was significantly different among regions in the old period, this was not the case in the recent period, resulting in uniformity throughout Japan.
CONCLUSIONS: The increasing ESRD rate is slowing in Japan, and its geographic differences, previously observed, have disappeared.

Entities:  

Mesh:

Year:  2011        PMID: 21638004     DOI: 10.1007/s10157-011-0466-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  20 in total

1.  Renoprotective action of statin estimated from mapping renal failure in Japan.

Authors:  Takeshi Usami; Naoyuki Nakao; Michio Fukuda; Atsuhiro Yoshida; Genjiro Kimura
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

2.  The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Svend Strandgaard; Anne-Lise Kamper; Giuseppe Maschio; Gavin Becker; Ronald D Perrone; Andrew S Levey
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

3.  Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark.

Authors:  V R Sørensen; P M Hansen; J Heaf; B Feldt-Rasmussen
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Regional variations in the incidence of end-stage renal failure in Japan.

Authors:  T Usami; K Koyama; O Takeuchi; K Morozumi; G Kimura
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

6.  Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.

Authors:  T Ecder; A B Chapman; G M Brosnahan; C L Edelstein; A M Johnson; R W Schrier
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

7.  Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.

Authors:  Yoshiyuki Furumatsu; Yasuyuki Nagasawa; Takayuki Hamano; Hirotsugu Iwatani; Kenichiro Iio; Tatsuya Shoji; Takahito Ito; Yoshiharu Tsubakihara; Enyu Imai
Journal:  Nephrol Dial Transplant       Date:  2007-10-23       Impact factor: 5.992

8.  Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; A M Johnson; P A Gabow; R W Schrier
Journal:  J Am Soc Nephrol       Date:  1994-12       Impact factor: 10.121

9.  Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Authors:  M Zeier; P Fehrenbach; S Geberth; K Möhring; R Waldherr; E Ritz
Journal:  Kidney Int       Date:  1992-11       Impact factor: 10.612

10.  Age distribution and yearly changes in the incidence of ESRD in Japan.

Authors:  Kunihiro Yamagata; Hideto Takahashi; Soh Suzuki; Kaori Mase; Masahiro Hagiwara; Yoshio Shimizu; Kouichi Hirayama; Masaki Kobayashi; Mitsuharu Narita; Akio Koyama
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

View more
  4 in total

1.  Decreased GM3 correlates with proteinuria in minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Shokichi Naito; Nagako Kawashima; Daisuke Ishii; Tetsuo Fujita; Masatsugu Iwamura; Yasuo Takeuchi
Journal:  Clin Exp Nephrol       Date:  2022-07-08       Impact factor: 2.617

Review 2.  Disparities in the burden, outcomes, and care of chronic kidney disease.

Authors:  Deidra C Crews; Yang Liu; L Ebony Boulware
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-05       Impact factor: 2.894

3.  Evidence of chronic kidney disease in veterans with incident diabetes mellitus.

Authors:  Justin Gatwood; Marie Chisholm-Burns; Robert Davis; Fridtjof Thomas; Praveen Potukuchi; Adriana Hung; Csaba P Kovesdy
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

4.  Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.

Authors:  Laura Plantinga; Virginia J Howard; Suzanne Judd; Paul Muntner; Rikki Tanner; Dana Rizk; Daniel T Lackland; David G Warnock; George Howard; William M McClellan
Journal:  Int J Health Geogr       Date:  2013-03-21       Impact factor: 3.918

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.